The current Covid-19 pandemic has led to an enormous amount of new primary research and clinical trials, which is crucial. However, in a possible rush to find treatments and new medications, it is of key importance to not lose sight of potential adverse effects.

One of the Adverse Effects Methods Group Co-convenors, Dr Daniela Junqueira, published a paper in the British Journal of Clinical Pharmacology (BJCP) which showed that the trials designed in the early stages of the pandemic had no or insufficient plans to measure adverse events. The paper can be accessed through this link: Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID‐19 pandemic.